Table 1. Biodistribution of ¹⁸F-CML in different organs of ICR mice.

Organ/Uptake	Intravenous administration (%ID)			Intragastric administration (%ID)
	5 min	60 min	120 min	5 min	60 min	120 min
Brain	3.04±0.02	0.38±0.01	0.07±0.00	1.04±0.02	0.31±0.03	0.02±0.01
Intestines	1.02±0.05	2.35±0.01	0.5±0.00	9.91±1.36	52.29±8.71	48.32±5.2
Stomach	0.35±0.02	0.02±0.01	0.01±0.00	76.85±7.01	29.73±3.91	17.87±2.1
Bladder	26.50±1.70	41.28±3.50	72.30±5.20	5.20±1.68	12.21±1.62	29.59±3.7
Lungs	1.65±0.05	1.12±0.02	0.25±0.00	0.35±0.19	0.51±0.11	0.23±0.05
Liver	17.28±2.04	9.72±1.62	3.28±0.05	1.17±0.45	1.0±0.12	0.29±0.05
Pancreas	0.9±0.04	0.01±0.0	0.00±0.02	0.2±0.01	0.32±0.02	0.05±0.00
Muscles	8.02±0.82	5.17±1.12	3.02±0.82	1.76±0.53	2.16±1.82	1.11±1.78
Kidneys	29.30±2.05	35.6±4.06	18.1±2.65	2.20±0.95	3.31±1.91	2.1±0.29
Heart	11.15±0.05	5.05±0.01	1.03±0.00	1.05±0.25	0.75±0.52	0.29±0.59

Radioactivity accumulation was expressed as the percentage of the injected dose per whole tissue (% ID) after a single intravenous injection or a single intragastric administration of 2 MBq of ¹⁸F-CML in 0.5 mL of saline with 2% ethanol at 3 different time points (n = 3/group, mean ± SD).